MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of investments
$179,000K
Proceeds from exercise of
stock options
$531K
Proceeds from espp stock
issuance
$523K
Net cash provided by
investing activities
$27,409K
Effect of foreign
exchange rate...
$842K
Net cash provided by
(used in) financing...
$570K
Canceled cashflow
$151,591K
Canceled cashflow
$484K
Net increase
(decrease) in cash, cash...
-$45,522K
Canceled cashflow
$28,821K
Stock-based compensation
expense
$29,613K
Accrued liabilities
$10,357K
Depreciation and
amortization
$9,262K
Non-cash lease expense
$6,019K
Provision for excess and
obsolete inventory
$3,468K
Accounts payable
$2,437K
Amortization of acquired
intangible assets
$1,715K
Prepaid expenses and
other assets
-$1,143K
Other non-cash items
$905K
Unrealized loss on equity
investments
-$602K
Purchases of short-term
marketable debt securities
$99,110K
Purchases of long-term
marketable debt securities
$32,321K
Purchases of property and
equipment
$8,303K
Purchases of marketable
equity securities
$6,857K
Purchase of convertible
note receivable
$5,000K
Payments for taxes
related to net share...
$484K
Net cash used in
operating activities
-$74,343K
Canceled cashflow
$65,521K
Net loss
-$74,896K
Deferred tax asset,
non-current
-$38,093K
Inventory
$11,524K
Operating lease
liabilities
-$6,415K
Change in fair value of
contingent consideration
-$3,177K
Accretion of discount on
short-term investments,...
$2,644K
Accounts receivable, net
$1,361K
Deferred revenue
-$1,314K
Change in fair value of
warrants
-$232K
Other liabilities
-$208K
Back
Back
Cash Flow
source: myfinsight.com
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)